- Clovis (NASDAQ:CLVS) has always been considered an acquisition target with a “long list” of potential suitors including Eli Lilly (NYSE:LLY), Merck & Co. (NYSE:MRK) , and Roche, Janney tells Bloomberg in an interview.
- CEO Patrick Mahaffy has sold other companies including Pharmion, NeXstar Pharmaceuticals.
- Clovis closed +12.7% and is up another 7.7% AH. Earlier today the stock jumped when Gilead (NASDAQ:GILD) said it is looking for cancer deals.
- Clovis's PDUFA date for ovarian cancer drug rucaparib is Feb. 23, 2017.